ELT Sight announced that the American Medical Association (AMA) approved two new Category III Current Procedural Terminology (CPT) codes to report ELT Sight’s ExTra Excimer Laser Trabeculostomy (ELT) procedure. The two new codes, to be used for reporting trabeculostomy ab interno by laser with or without the use of an ophthalmic endoscope, are effective January 1, 2021.
The company’s ExTra ELT device is a specialized excimer laser system used for microinvasive glaucoma surgery (MIGS) to lower eye pressure in patients with glaucoma. The product has already received a CE mark in Europe, where ELT has been the subject of numerous scientific publications. Review of published clinical studies using a new technology is a critical factor in the approval process of a CPT application. Preparations are underway to begin clinical trials of the device in the United States and to expand its international use.
The CPT system is a set of standardized codes to communicate nationwide medical procedures and services across health care systems and professionals, including health insurance companies, physicians, hospital facilities and laboratories. The issuance of a Category III code, a temporary code to describe emerging technologies, services and procedures, is an essential step toward a future permanent Category I code, used for widespread reimbursement of procedures performed in medical practices.
“Multiple clinical studies across Europe have demonstrated that ExTra ELT has a strong efficacy and safety profile, with significant advantages over other forms of microinvasive glaucoma surgery (MIGS),” said Elliot Friedman, Chief Executive Officer of ELT Sight. “Obtaining two CPT codes from AMA is an important milestone for ELT Sight and a critical step in positioning the company to become a leader in the surgical treatment of glaucoma.”